Union Bancaire Privee
BMRN icon

Union Bancaire Privee’s BioMarin Pharmaceuticals BMRN Stock Holding History

Union Bancaire Privee’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,459
Closed -$149K – 507
2025
Q3 		$149K Buy
+3,459
New +$198K ﹤0.01% 386
2025
Q1 		– Sell
-3,000
Closed -$196K – 514
2024
Q4 		$196K Buy
+3,000
New +$201K ﹤0.01% 408

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Union Bancaire Privee's BMRN Position: Q4 2025 in Review

Union Bancaire Privee sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 3,459 shares — an estimated $149K sold.

Union Bancaire Privee first reported a position in BMRN in Q4 2024 and held it in 2 quarters. The position peaked at $196K in Q4 2024. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

  • Union Bancaire Privee reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Union Bancaire Privee sold 3,459 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $149K.
  • Union Bancaire Privee first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Union Bancaire Privee's BioMarin Pharmaceuticals position peaked at $196K in Q4 2024.
  • 540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Union Bancaire Privee's 13F filing for Q4 2025, filed 5 Jan 2026.